Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane. O'Shaughnessy, J., Piccart, M., Schwartzberg, L. S., Cortes, J., Harbeck, N., Im, S., Rugo, H. S., Untch, M., Yardley, D. A., Bondarenko, I., Chan, S., Dieras, V., Pegram, M. D., Kroll, S., O'Connell, J. P., Vacirca, J., Wei, T., Tang, K., Seidman, A. AMER SOC CLINICAL ONCOLOGY. 2019
View details for DOI 10.1200/JCO.2019.37.15_suppl.TPS1107
View details for Web of Science ID 000487345803227